Diagnostik und Therapie des hepatozellulären Karzinoms

Primäre Tumorerkrankungen der Leber nehmen kontinuierlich zu, die häufigste Form ist das hepatozelluläre Karzinom. Überwiegend betroffen sind Männer mit einer viral, metabolisch und/oder durch Alkohol bedingten Leberzirrhose. In den letzten Jahren haben sich stadienabhängig viele verschiedene Therapiemodalitäten etabliert, die im Rahmen einer interdisziplinären Betreuung eingesetzt werden können. Dieser Beitrag gibt einen aktuellen Überblick.

Publication History

Article published online:
04 October 2021

• Literatur

• 1 Galle PR, Former A, Llovet J. et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236
• 2 Globocan 2018. Cancer Fact Sheet: Liver Cancer. March 2019. Im Internet (Stand: 29.06.2020): http://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf
• 3 Kanwal F, Kramer JR, Mapakshi S. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 2018; 155: 1828-1837
• 4 Kanwal F, Kramer JR, Asch SM. et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology 2020; 71: 44-55
• 5 Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V. et al. Type 2 diabetes and metformin use associate with outcomes of patients with non-alcoholic steatohepatitis-related, Child-Pugh A cirrhosis. Clin Gastroenterol Hepatol 2020;
• 6 Vogel A, Cervantes A, Chau I. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv238-iv255
• 7 Tzartzeva K, Obi J, Rich NE. et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018; 154: 1706-1718
• 8 Best J, Bechmann LP, Sowa JP. et al. GALAD Score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020; 18: 728-735
• 9 Ioannou GN, Beste LA, Green PK. et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB‑4 scores. Gastroenterology 2019; 157: 1264-1278
• 10 Mazzaferro V, Sposito C, Zhou J. et al. Metroticket 2.0 Model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018; 154: 128-139
• 11 Bundesärztekammer. Richtlinien zur Organtransplantation gem. § 16 Abs. 1 S. 1 Nrn. 2u. 5 TPG. Dtsch Arztebl 2013; 110: A‑241/B-225/C-225
• 12 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64
• 13 Llovet JM, Ricci S, Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
• 14 Kudo M, Finn RS, Qin S. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391: 1163-1173
• 15 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382: 1894-1905
• 16 Bruix J, Qin S, Merle P. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66
• 17 Abou-Alfa GK, Meyer T, Cheng AL. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379: 54-63
• 18 Zhu AX, Kang YK, Yen CJ. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH‑2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282-296
• 19 Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology 2019; 70: 1437-1442